Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Liabilities (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $223.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 22.7% to $223.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $223.2 million through Dec 2025, up 22.7% year-over-year, with the annual reading at $223.2 million for FY2025, 22.7% up from the prior year.
  • Other Non-Current Liabilities hit $223.2 million in Q4 2025 for United Therapeutics, up from $214.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $223.2 million in Q4 2025 to a low of $67.4 million in Q3 2023.
  • Historically, Other Non-Current Liabilities has averaged $125.4 million across 5 years, with a median of $99.6 million in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 34.88% in 2023 and later skyrocketed 133.8% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $104.8 million in 2021, then dropped by 0.19% to $104.6 million in 2022, then decreased by 25.62% to $77.8 million in 2023, then surged by 133.8% to $181.9 million in 2024, then rose by 22.7% to $223.2 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for UTHR at $223.2 million in Q4 2025, $214.6 million in Q3 2025, and $207.3 million in Q2 2025.